Anesthesia progress最新文献_第2页

Stability of Epinephrine in a Normal Saline Solution. 正常生理盐水中肾上腺素的稳定性

Anesthesia progress Pub Date : 2024-09-09 DOI: 10.2344/998301

Caroline M Sawicki, Daniel B McKim, Hongrui Wang, Morgan Vasas, Joshua J Blakeslee, Courtney A Jatana, Patrick Dib, Bryant W Cornelius, Spencer D Wade

{"title":"Stability of Epinephrine in a Normal Saline Solution.","authors":"Caroline M Sawicki, Daniel B McKim, Hongrui Wang, Morgan Vasas, Joshua J Blakeslee, Courtney A Jatana, Patrick Dib, Bryant W Cornelius, Spencer D Wade","doi":"10.2344/998301","DOIUrl":"10.2344/998301","url":null,"abstract":"Objective: Dilution of concentrated epinephrine prior to intravenous use during clinical emergencies can delay urgent interventions. The objective of this study was to determine whether diluted epinephrine remains stable and sterile over time in common hospital settings.Methods: Epinephrine samples were prepared by clinically relevant double dilution techniques. Samples were stored in 10-mL syringes and incubated under 1 of 4 simulated hospital environments with a mixture of lighting and temperature settings: 4°C/20°C, with or without fluorescent lighting. Samples were incubated for 0, 15, 30, 60, or 90 days. Capillary zonal electrophoresis was used to quantify the concentration of epinephrine and/or presence of any degradation products. All samples were tested for the presence of bacterial growth using blood agar cultures.Results: Diluted epinephrine samples remained stable for up to 90 days in all 4 simulated clinical storage conditions. No bacterial colony-forming units were detected in any of the environmental samples regardless of incubation duration, light, or temperature conditions.Conclusion: Diluted epinephrine for anticipated clinical emergencies may remain clinically useful for up to 90 days, thus improving patient safety, access to medications, and overhead costs by reducing waste.","PeriodicalId":94296,"journal":{"name":"Anesthesia progress","volume":"71 3","pages":"109-114"},"PeriodicalIF":0.0,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11387972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142585111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Review of Inherited Coagulation Disorders. 遗传性凝血障碍综述。

Anesthesia progress Pub Date : 2024-07-08 DOI: 10.2344/anpr-71-2_continuing_edu

Tiffany Hoang, Regina A E Dowdy

{"title":"Review of Inherited Coagulation Disorders.","authors":"Tiffany Hoang, Regina A E Dowdy","doi":"10.2344/anpr-71-2_continuing_edu","DOIUrl":"10.2344/anpr-71-2_continuing_edu","url":null,"abstract":"Most invasive dental procedures elicit some degree of bleeding which ultimately leads to clotting and eventual hemostasis. However, patients with inherited coagulation disorders may exhibit prolonged or, in some cases, excessive bleeding requiring multiple perioperative interventions. Von Willebrand disease is the most common inherited coagulopathy and often manifests via easy bruising, epistaxis, or prolonged bleeding. Hemophilia A (factor VII) and B (factor IX) are factor deficiencies that are clinically indistinguishable and managed according to severity and the required dental treatment. Other coagulopathies are rare (ie, inheritance is autosomal recessive) and may only become evident in homozygotes or compound heterozygotes. Current lab values and medical consultation with the patient's hematologist are imperative prior to rendering invasive dental treatment. There are a myriad of sedation and general anesthesia considerations, including risks for epistaxis with nasal instrumentation and bruising with improper patient positioning. Preoperative treatment with desmopressin or factor replacement may be required and generally should facilitate normal hemostasis. Additional therapies should be considered to help ensure adequate postoperative hemostasis, including pressure dressings, resorbable clotting materials, laser therapy, and oral rinses.","PeriodicalId":94296,"journal":{"name":"Anesthesia progress","volume":"71 2","pages":"87-95"},"PeriodicalIF":0.0,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11259365/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142585039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Review of Current Literature of Interest to the Office-Based Anesthesiologist. 办公室麻醉师感兴趣的最新文献综述。

Anesthesia progress Pub Date : 2024-07-08 DOI: 10.2344/809216

Mark A Saxen

引用次数: 0

In Memoriam: Dr Stuart E. LieblichOctober 14, 1955-February 28, 2024. 悼念Stuart E. Lieblich 博士1955 年 10 月 14 日-2024 年 2 月 28 日。

Anesthesia progress Pub Date : 2024-07-08 DOI: 10.2344/anpr-566035

Robert C Bosack

引用次数: 0

Use of Rocuronium and Sugammadex for a Patient With Controlled Polymyositis: A Case Report. 为一名多发性肌炎患者使用罗库溴铵和舒加迈德：病例报告。

Anesthesia progress Pub Date : 2024-07-08 DOI: 10.2344/021627

Hidetaka Kuroda, Tomomi Katayama, Atsuki Yamaguchi, Norika Katagiri, Shota Tsukimoto, Uno Imaizumi, Takuro Sanuki

{"title":"Use of Rocuronium and Sugammadex for a Patient With Controlled Polymyositis: A Case Report.","authors":"Hidetaka Kuroda, Tomomi Katayama, Atsuki Yamaguchi, Norika Katagiri, Shota Tsukimoto, Uno Imaizumi, Takuro Sanuki","doi":"10.2344/021627","DOIUrl":"10.2344/021627","url":null,"abstract":"Muscle relaxants and their reverse drugs should be carefully administered to patients with acute polymyositis and/or dermatomyositis. However, the use of these drugs in controlled polymyositis and/or dermatomyositis is controversial. This case report describes the use of rocuronium and sugammadex in a 27-year-old female patient with controlled polymyositis who was scheduled for minor oral surgery under general anesthesia. General anesthesia was induced rapidly, and 0.66 mg/kg of rocuronium was administered prior to nasotracheal intubation. No additional muscle relaxants were administered during the surgery. At the end of surgery, approximately 2 hours after the rocuronium was administered, her train-of-four (TOF) ratio was still 49%. A dose of 3.3 mg/kg of sugammadex was administered, and it took 12 minutes for the TOF ratio to exceed 90%. The prolonged duration of muscle relaxation in patients with polymyositis may be due to a decrease in skeletal muscle and capillary volume. The slow onset of sugammadex may be caused by slow diffusion of rocuronium from the neuromuscular junction. Patients with polymyositis require close perioperative neuromuscular function monitoring, regardless of their disease control status.","PeriodicalId":94296,"journal":{"name":"Anesthesia progress","volume":"71 2","pages":"81-84"},"PeriodicalIF":0.0,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11259364/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142585050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact Factor for Journals Specializing in Dental Anesthesiology. 牙科麻醉学专业期刊的影响因子。

Anesthesia progress Pub Date : 2024-07-08 DOI: 10.2344/563377

Takuro Sanuki, Shota Tsukimoto, Hidetaka Kuroda, Kanta Kido

引用次数: 0

Tracheal Stenosis Detected During Endotracheal Intubation in a Patient With Down Syndrome. 一名唐氏综合征患者在气管插管时发现气管狭窄。

Anesthesia progress Pub Date : 2024-07-08 DOI: 10.2344/anpr-63-16-65

Tomoaki Ujita, Toru Yamamoto, Yutaka Tanaka, Shigenobu Kurata, Kenji Seo

引用次数: 0

Comparison of Anesthetics for Laryngeal Mask Airway Insertion: A Network Meta-Analysis. 喉罩气道插入麻醉剂的比较：网络 Meta 分析

Anesthesia progress Pub Date : 2024-07-08 DOI: 10.2344/22-00033

Cameron Goertzen, Erin Goertzen, Maryam Zanjir, Christopher Dare, Amir Azarpazhooh, Michelle Wong

{"title":"Comparison of Anesthetics for Laryngeal Mask Airway Insertion: A Network Meta-Analysis.","authors":"Cameron Goertzen, Erin Goertzen, Maryam Zanjir, Christopher Dare, Amir Azarpazhooh, Michelle Wong","doi":"10.2344/22-00033","DOIUrl":"10.2344/22-00033","url":null,"abstract":"Objective: This study aimed to establish which anesthetic agents are associated with minimized adverse outcomes during laryngeal mask airway (LMA) insertion.Methods: Databases were searched for randomized controlled trials (RCTs) with American Society of Anesthesiologists I or II adult patients (≥15 years of age) receiving general anesthesia (GA) with an LMA. Propofol only was the comparator to other anesthetics used during LMA insertion. The primary outcome was prolonged apnea, and secondary outcomes were adverse airway events, LMA insertion failure, inadequate depth of anesthesia, and hemodynamic events. A network meta-analysis was conducted to estimate the treatment effects (odds ratios, 95% credible intervals, and surface under the cumulative ranking curve [SUCRA]).Results: A total of 28 anesthetic combinations used on 4695 patients for GA induction and LMA insertion were examined across 53 RCTs. Overall, there was an apnea incidence rate of 33.3% (849 of 2548) with a mean time of 3.74 ± 3.56 minutes (n = 3091). Propofol + dexmedetomidine had the highest overall summed score of SUCRA ranks in reducing adverse outcomes (apnea incidence: SUCRA = 37%, apnea time: SUCRA = 66%, airway adverse event: SUCRA = 67%, insertion failure: SUCRA = 73%, inadequate depth of anesthesia: SUCRA = 84%). In comparison among all propofol combinations, propofol alone ranked lowest for overall summed score of SUCRA in reducing adverse outcomes (apnea incidence: SUCRA = 47%, apnea time: SUCRA = 71%, airway adverse event: SUCRA = 9%, insertion failure: SUCRA = 20%, inadequate depth of anesthesia: SUCRA = 9%).Conclusion: All anesthetic combinations, other than those with thiopental, reduced adverse outcomes as compared with propofol alone. The combination of propofol and dexmedetomidine infused over 10 minutes ranked as the most effective for reducing adverse outcomes during LMA insertion.","PeriodicalId":94296,"journal":{"name":"Anesthesia progress","volume":"71 2","pages":"58-75"},"PeriodicalIF":0.0,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11259371/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142584508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Joint Meeting of the IFDAS 17th Triennial Congress and the ADSA Annual Session Held in Las Vegas. 在拉斯维加斯举行的第 17 届国际民主与社会科学联合会（IFDAS）三年一度的大会和 ADSA 年会联席会议。

Anesthesia progress Pub Date : 2024-07-08 DOI: 10.2344/025134

Jason Brady

引用次数: 0

Continued Updates to Anesthesia Progress. 继续更新麻醉进展。

Anesthesia progress Pub Date : 2024-07-08 DOI: 10.2344/746154

Kyle J Kramer

引用次数: 0